Canadian Biopharmaceutical Company AEterna Zentaris Inc. (NASDAQ:AEZS) said Wednesday it turned a $12 million profit in the fourth quarter. AEterna Zentaris Inc. trades on the “NASDAQ” under the stock symbol “AEZS”. For More information regarding the "AEZS", make sure to visit the Most Exclusive and In Depth newsletter website at: http://www.wallstreetgrand.com/.
Join today and be part of the best free investment newsletter on the web where we focus on market moving news.
Canadian Biopharmaceutical Company AEterna Zentaris Inc. (NASDAQ:AEZS) said Wednesday it turned a $12 million profit in the fourth quarter as license fees rose while research expenses fell.
The company earned 19 cents per share in the three months that ended Dec. 31. That compares with a loss of $14.5 million, or 27 cents per share, for the same quarter in 2008
AEterna said revenue rose largely due to the company recognizing the remaining unamortized portion, or about $30.4 million, of a payment received from French drug maker Sanofi-Aventis as part of a developing and marketing agreement.
AEterna said license fees rose to $35.2 million from $2.1 million in the fourth quarter while research and development expenses fell $1.6 million to $10.7 million. That was partially offset by an increase in selling, general and administrative expenses.
You can contact us during market hours at 1-888-9-ClubGrand (1888-925-8247) or via email at staff@wallstreetgrand.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including 2009 growth, revenue for the second quarter and year of 2009 and gross margin for the second quarter and year of 2009. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the impact of intense competition, the continuation or worsening of current economic conditions and the condition of the domestic and global credit and capital markets.
Disclaimer:
Wall Street Grand LLC has not been compensated by the company for this press release and does not expect to be compensated in the future for any type of awareness. To read our full disclaimer clicks the link http://www.wallstreetgrand.com/disclosure.html
